{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:43Z","timestamp":1772165623507,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platelet (PLT) transfusion was the most practical way to increase patients\u2019 PLT counts before invasive hepatic procedures such as radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). A novel drug that raises the PLT count by acting on the thrombopoietin receptor has recently become available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Lusutrombopag 3\u00a0mg was administered daily for 7 days to patients who underwent RFA for liver tumors with low PLT counts (&lt;\u200950,000 PLT \u00b5L\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      ). We collected demographic data concerning the patients\u2019 liver function and PLT counts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Lusutrombopag was administered to 91 patients, with a median age of 71 years (range 51\u201386). Forty-two patients had hepatitis C, 12 had hepatitis B, 21 had alcoholic liver disease, 11 had nonalcoholic steatohepatitis, and five had other diseases. The median Child-Pugh score was 7 (range 5\u201311). Thirty-seven patients had stage I tumors, 41 had Stage II, 12 had stage III, and one had stage IV. PLT count was elevated from 4.4\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      \u2009\u00b1\u20091.4\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      to 8.6\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      \u2009\u00b1\u20092.5\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      PLT \u00b5L\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      . Lusutrombopag administration prevented PLT transfusions in 84\/91 patients (92%). No patient had bleeding complications after RFA. One had portal thrombosis after lusutrombopag administration. Patients who achieved PLT counts of &gt;\u200950,000 PLT \u00b5L\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      had higher PLT counts before lusutrombopag administration. The degree of splenomegaly did not affect the rate of PLT count elevation. There was no specific adverse effect by administrating lusutrombopag for patients with PLT counts of around 50,000 \u00b5L\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      but &gt;\u200950,000 \u00b5L\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lusutrombopag administration before RFA was effective and seemed to be relatively safe for hepatocellular carcinoma patients with low PLT counts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study was approved by Japanese Red Cross Medical Center Institutional Reseach Comittie (#862, 07\/03\/2016), and was registered in a publically accessible primary register (#UMIN000046629, registered date: 14\/01\/2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-02879-0","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T04:02:33Z","timestamp":1690171353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Hideo","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kanezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Teratani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinpei","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Obi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2879_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/MCG.0b013e3181b7ed76","volume":"44","author":"E Goto","year":"2010","unstructured":"Goto E, Tateishi R, Shiina S, Masuzaki R, Enooku K, Sato T, et al. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. J Clin Gastroenterol. 2010;44:374\u201380.","journal-title":"J Clin Gastroenterol"},{"key":"2879_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","volume":"37","author":"M Peck-Radosavljevic","year":"2017","unstructured":"Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37:778\u201393.","journal-title":"Liver Int"},{"issue":"4","key":"2879_CR3","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep.30561","volume":"70","author":"M Peck-Radosavljevic","year":"2019","unstructured":"Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70(4):1336\u201348.","journal-title":"Hepatology"},{"key":"2879_CR4","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","volume":"17","author":"H Hidaka","year":"2019","unstructured":"Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol. 2019;17:1192\u2013200.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2879_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00535-018-1499-2","volume":"54","author":"R Tateishi","year":"2019","unstructured":"Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, et al. A randomized controlled trial of lusutrombopag in japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2019;54:171\u201381.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2879_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12876-020-01573-9","volume":"20","author":"H Nomoto","year":"2020","unstructured":"Nomoto H, Morimoto N, Miura K, Watanabe S, Takaoka Y, Maeda H, et al. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study. BMC Gastroenterol. 2020;20(1):427.","journal-title":"BMC Gastroenterol"},{"key":"2879_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.sla.0000254368.65878.da","volume":"245","author":"M Minagawa","year":"2007","unstructured":"Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assesment of the japanese TNM and AJCC\/UICC TNM systems in a cohort of 12,772 patients in Japan. Ann Surg. 2007;245:909\u201322.","journal-title":"Ann Surg"},{"key":"2879_CR8","doi-asserted-by":"crossref","unstructured":"Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification seminars in liver disease 1999; 19(3): 329\u201338.","DOI":"10.1055\/s-2007-1007122"},{"key":"2879_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/hepr.13305","volume":"49","author":"T Ishikawa","year":"2019","unstructured":"Ishikawa T, Okoshi M, Tomiyoshi K, Kojima Y, Horigome R, Imai M, et al. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res. 2019;49:590\u20133.","journal-title":"Hepatol Res"},{"key":"2879_CR10","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.3748\/wjg.v24.i46.5271","volume":"24","author":"H Uojima","year":"2018","unstructured":"Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, et al. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018;24:5271\u20139.","journal-title":"World J Gastroenterol"},{"key":"2879_CR11","doi-asserted-by":"publisher","first-page":"e0211122","DOI":"10.1371\/journal.pone.0211122","volume":"14","author":"H Takada","year":"2019","unstructured":"Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, et al. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS ONE. 2019;14:e0211122.","journal-title":"PLoS ONE"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02879-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02879-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02879-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T04:04:08Z","timestamp":1690171448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02879-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2879"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02879-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2423711\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (#862) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The experimental protocol was approved by Japanese Red Cross Medical Center institutional committee. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"250"}}